Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC

Clinical trial NCT06841874 · NO_LONGER_AVAILABLE

Trial details

NCT number: NCT06841874
Sponsor: Nuvation Bio Inc.
Status: NO_LONGER_AVAILABLE
Study type: EXPANDED_ACCESS

Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma Bronchogenic Carcinoma Non Small Cell Carcinoma of the Lung ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.